Is Belite Bio (BLTE) A Bargain Following Its Japan Tinlarebant Filing?
Belite Bio (BLTE) drew fresh attention after announcing a New Drug Application in Japan for tinlarebant in Stargardt disease type 1, using the country’s Sakigake expedited review pathway.
Belite Bio shares trade at US$170.96, with a 30 day share price return of 6.15% and a 90 day share price return of 16.24%. The 1 year total shareholder return of 143.53% and 3 year total shareholder return of about 4.4x suggest momentum has been strong as investors weigh the tinlarebant NDA progress and changing perceptions of risk around the pipeline.
Scan how Belite Bio fits into the wider rare-disease opportunity set and compare it with 16 high quality undiscovered gems with similar clinical potential and fundamentals.
Belite Bio shares have surged on the tinlarebant NDA story, yet sit well below both analyst targets and intrinsic value estimates. Which side of that gap better reflects where fair value lies today?
Most Popular Narrative: 24% Undervalued
Belite Bio is trading at $170.96 against a widely followed fair value estimate of about $223.89. This frames the whole tinlarebant story through a valuation lens that assumes significant future execution on both Stargardt disease and geographic atrophy.
A strong year end cash position of US$772.6 million against planned three year R&D spend of about US$150 million and commercialization spend of about US$200 million to US$250 million reduces near term funding risk and allows the company to build its field force, market access and medical affairs infrastructure in advance, which can support revenue ramp and help scale margins if the launches are successful.
See why 3 investors see Belite Bio as 24% undervalued.
Result: Fair Value of $223.89 (UNDERVALUED)
Still, the Belite Bio story could shift quickly if regulators request extra Stargardt data or if the PHOENIX geographic atrophy trial produces underwhelming results.
Find out about the key risks to this Belite Bio narrative.
Another View on Belite Bio’s Valuation
There is a very different number in the background. Our DCF model points to a fair value of about $967.92 for Belite Bio, which is far above both the $223.89 narrative fair value and the current $170.96 share price. Is that a genuine margin of safety or just optimistic modeling?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
Mixed messages on Belite Bio’s value and risk profile can be confusing, so move quickly, review the full data, and weigh the 2 key rewards and 2 important warning signs.
Looking for more Belite Bio sized opportunities?
Belite Bio might already be on your radar, but you do not want your next big idea to slip by while you stay focused on a single ticker.
- Explore resilient potential by scanning 30 resilient stocks with low risk scores to help keep portfolio drawdowns in check when conditions turn rough.
- Look for quality at a discount with the 35 high quality undervalued stocks that highlights businesses combining sound fundamentals with appealing price tags.
- Seek steadier payout potential through the 7 dividend fortresses that focuses on income ideas with higher yield profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com